|
MechanismcGMP-PDE inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date30 Oct 1997 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismTGF-β inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Oleolive, Inc.
0 Patents (Medical) associated with Oleolive, Inc.
100 Deals associated with Oleolive, Inc.
100 Translational Medicine associated with Oleolive, Inc.